Antivirals key to MAC prevention regimen.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017963:Azithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D017828:Rifabutin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D017828:Rifabutin; D017963:Azithromycin; D017291:Clarithromycin